Barclays analyst Carter Gould lowered the price target on Gilead Sciences ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Form 4 GILEAD SCIENCES, INC. For: Apr 25 Filed by: Telman Deborah HApril 26, 2024 4:31 PM FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIVApril 26, 2024 10:43 AM Gilead Sciences (GILD) PT Lowered to $80 at JefferiesApril 26, 2024 8:56 AM Gilead Sciences (GILD) PT Lowered to $78 at Morgan StanleyApril 26, 2024 8:36 AM Gilead Sciences (GILD) Announces FDA Approves Biktarvy Label Update With Data For Pregnant Adults With HIVApril 26, 2024 8:03 AM Gilead Sciences (GILD) PT Lowered to $74 at RBC CapitalApril 26, 2024 6:24 AM Gilead Sciences (GILD) Misses Q1 EPS by 288cApril 25, 2024 4:54 PM Gilead posts quarterly loss on acquisition charge, revenue rises 5%April 25, 2024 4:11 PM Form 8-K GILEAD SCIENCES, INC. For: Apr 25April 25, 2024 4:05 PM Gilead Sciences Announces First Quarter 2024 Financial ResultsApril 25, 2024 4:02 PM